

# Non-Surgical Biotherapeutic Solutions for Tissue Repair & Regeneration



**Validated enzymatic technology platform: NexoBrid® a commercial drug for severe burns; EscharEx® a late-stage therapy for wound care; MW005 a clinical-stage biotherapy for non-melanoma skin cancers**



**Strategic collaborations with BARDA, Vericel and DoD (U.S.), Kaken (Japan), BSV (India)**



**Strong Balance sheet**



## EscharEx®: The Game Changer

**Next generation enzymatic debridement solution for chronic and hard-to-heal wounds**

Significant unmet medical need for topical, rapid and effective debridement agent in outpatient settings

In controlled studies, significantly higher incidence of complete debridement using EscharEx® (9 days vs. 59 days for patients treated with SOC)

Achieved complete debridement with avg 3.6 topical applications compared to 12.8 with SOC

Demonstrated safe, effective and rapid debridement in VLU and DFU; reduced wound size, reduction in biofilm and bacterial burden

Sets a new bar for efficacy; \$2B market opportunity - anticipated to draw market share from all other debridement modalities

Phase III study design discussions with the FDA

## Solid balance sheet to support EscharEx® clinical development program

Cash of \$65M

2022 revenues of ~\$26-27M, NexoBrid is profitable

2023 product revenues >50% growth

## NexoBrid®: Profitable & Validated

**Topical bioactive therapy for burn care; FDA approved for the treatment of severe thermal burns in adults.**

Clear unmet need for early, effective and selective non-surgical eschar removal for severe burns

Clinically and commercially validated

Strategic alliances: BARDA (US), Vericel (US), DoD (US), Kaken (JP), BSV (IN)

Approved in 44 countries; more than 12k patients treated successfully WW

Anticipated EU (EMA) pediatric label extension approval in mid 2023

## MW005: Novel Biotherapy

**Topical biological drug for the treatment of basal cell carcinoma (BCC)**

Investigational drug containing a sterile mixture or proteolytic enzymes

Easy to use, high potency, 5-7 topical applications

US Phase I/II study, demonstrated efficacy, safety and tolerability

4.3M annual cases of Basal Cell Carcinomas diagnosed in the US